MedTrace Logo

Phase 2a Study to Evaluate the Efficacy and Safety of MEDI9929 in Adults With Atopic Dermatitis

NCT02525094 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 113

Last updated 2018-02-15

Study results available
· View outcomes & findings →

Summary

To assess the efficacy and safety of MEDI9929 in adult subjects with Atopic Dermatitis

Conditions

Interventions

BIOLOGICAL

MEDI9929

Participants will receive 6 subcutaneous doses of MEDI9929 280 mg every 2 weeks for 12 weeks, with the last dose at Week 10.

BIOLOGICAL

Placebo

Participants will receive 6 subcutaneous doses of placebo every 2 weeks for 12 weeks, with the last dose at Week 10.

Sponsors & Collaborators

  • Amgen

    collaborator INDUSTRY

  • MedImmune LLC

    lead INDUSTRY

Principal Investigators

  • Eric Simpson, MD · Oregon Health and Science University

  • Roderick Mcphee, MD · MedImmune LLC

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-08-15
Primary Completion
2016-05-09
Completion
2016-07-15
FDA Drug
Yes

Countries

  • United States
  • Australia
  • Canada
  • Germany
  • Hungary
  • New Zealand

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02525094 on ClinicalTrials.gov